Tag Archives: Mark Breidenbach

Alpine Immune Sciences Inc (ALPN) Receives a Buy from Oppenheimer

Oppenheimer analyst Mark Breidenbach reiterated a Buy rating on Alpine Immune Sciences Inc (ALPN – Research Report) yesterday and set a price target of $13. The company’s shares closed yesterday at $7.19. Breidenbach commented: “Monday, Alpine reported 4Q earnings and

VolitionRX (VNRX) Receives a Buy from Oppenheimer

Oppenheimer analyst Mark Breidenbach maintained a Buy rating on VolitionRX (VNRX – Research Report) today and set a price target of $5. The company’s shares closed yesterday at $2.97. Breidenbach said: “Thursday, VolitionRx reported 4Q results and provided a business

Gamida Cell Ltd (GMDA) Receives a Buy from Oppenheimer

Oppenheimer analyst Mark Breidenbach reiterated a Buy rating on Gamida Cell Ltd (GMDA – Research Report) today and set a price target of $20. The company’s shares opened today at $13.60, close to its 52-week high of $15.41. Breidenbach said:

Analysts Offer Insights on Healthcare Companies: Gamida Cell Ltd (NASDAQ: GMDA) and Nevro (NYSE: NVRO)

Companies in the Healthcare sector have received a lot of coverage today as analysts weigh in on Gamida Cell Ltd (GMDA – Research Report) and Nevro (NVRO – Research Report). Gamida Cell Ltd (GMDA) Oppenheimer analyst Mark Breidenbach maintained a

Oppenheimer Keeps Their Buy Rating on Alpine Immune Sciences Inc (ALPN)

Oppenheimer analyst Mark Breidenbach maintained a Buy rating on Alpine Immune Sciences Inc (ALPN – Research Report) yesterday and set a price target of $13. The company’s shares closed yesterday at $5.74. Breidenbach wrote: “Monday, Alpine announced that dosing has

Oppenheimer Remains a Buy on Forty Seven Inc (FTSV)

Oppenheimer analyst Mark Breidenbach maintained a Buy rating on Forty Seven Inc (FTSV – Research Report) today and set a price target of $35. The company’s shares closed yesterday at $15.91. Breidenbach said: “Wednesday, we met with management to review